Close
Help





JOURNAL

Clinical Medicine Reviews in Vascular Health

Tadalafil Once-Daily: Patient and Partner Perspective in the Management of Erectile Dysfunction

Submit a Paper


Clinical Medicine Reviews in Vascular Health 2011:3 107-116

Published on 31 Jul 2011

DOI: 10.4137/CMRVH.S1570


Further metadata provided in PDF

Download Article PDF


Sign up for email alerts to receive notifications of new articles published in Clinical Medicine Reviews in Vascular Health

Abstract

Phosphodiesterase type 5 (PDE5) inhibitors are arguably the gold standard for treatment of erectile dysfunction in men. While all three PDE5 inhibitors approved for use in the U.S. are effective in treating ED, they possess different characteristics. Tadalafil differs from both sildenafil and vardenafil in its long half-life, which makes it ideal for daily dosing. This regimen has been shown to be effective over placebo, and studies suggest that it may be preferable by both partners over on-demand dosing. Side effects are typically mild in nature and infrequently lead to discontinuation of the drug. Once-daily dosing has also shown to be effective in ‘difficult-to-treat’ groups, such as diabetics and non-responders to on-demand therapy. The implementation of once-daily therapy represents a significant advancement in the understanding of male erectile dysfunction.



Downloads

RIS citation   (ENDNOTE, REFERENCE MANAGER, PROCITE, REFWORKS)

BibTex citation   (BIBDESK, LATEX)





Quick Links


New article and journal news notification services